Key Highlights

  • Psyence Biomedical shares closed up 24% at $4.42.
  • The move followed President Trump's commitment to broaden ibogaine research and Right to Try access.
  • The University of Miami donated its 1994 ibogaine IND to the federal government.
  • The news fueled market interest in psychedelic clinical programs targeting PTSD, alcohol use disorder, and substance use disorder.

Psyence Biomedical Ltd. (NASDAQ: PBM) shares closed up 24% at $4.42 following President Trump's commitment to broaden ibogaine research and Right to Try access.

What Happened

The momentum was sparked by the University of Miami donating its 1994 ibogaine IND to the federal government, fueling market interest in psychedelic clinical programs targeting PTSD, alcohol use disorder, and substance use disorder.

Market Reaction

Shares rose sharply as investors responded to the broader policy signal around ibogaine research, viewing it as a potential tailwind for companies with psychedelic-focused clinical programs, including Psyence Biomedical.

Outlook

Continued developments in federal policy toward ibogaine research and Right to Try access are likely to remain relevant for sentiment toward psychedelic-focused clinical-stage companies like Psyence Biomedical.